- Home
- MIST vs INM Comparison
MIST vs INM Comparison
Compare MIST & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- INM
- Stock Information
- Founded
- MIST 2003
- INM 1981
- Country
- MIST Canada
- INM Canada
- Employees
- MIST N/A
- INM N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- INM Health Care
- Exchange
- MIST Nasdaq
- INM Nasdaq
- Market Cap
- MIST 53.9M
- INM 3.2M
- IPO Year
- MIST N/A
- INM N/A
- Fundamental
- Price
- MIST $1.12
- INM $2.33
- Analyst Decision
- MIST Strong Buy
- INM
- Analyst Count
- MIST 2
- INM 0
- Target Price
- MIST $9.50
- INM N/A
- AVG Volume (30 Days)
- MIST 1.6M
- INM 46.6K
- Earning Date
- MIST 05-20-2025
- INM 05-13-2025
- Dividend Yield
- MIST N/A
- INM N/A
- EPS Growth
- MIST N/A
- INM N/A
- EPS
- MIST N/A
- INM N/A
- Revenue
- MIST N/A
- INM $4,832,013.00
- Revenue This Year
- MIST N/A
- INM N/A
- Revenue Next Year
- MIST N/A
- INM N/A
- P/E Ratio
- MIST N/A
- INM N/A
- Revenue Growth
- MIST N/A
- INM N/A
- 52 Week Low
- MIST $0.63
- INM $1.72
- 52 Week High
- MIST $2.75
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- MIST 46.48
- INM 34.09
- Support Level
- MIST $1.28
- INM $2.70
- Resistance Level
- MIST $1.32
- INM $3.20
- Average True Range (ATR)
- MIST 0.12
- INM 0.23
- MACD
- MIST 0.03
- INM -0.05
- Stochastic Oscillator
- MIST 38.80
- INM 5.26
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.